Marieke van Son

38 CHAPTER 2 REFERENCES 1. Tamada S, Ninomiya N, Kitamoto K, et al. Comparative effectiveness of radical prostatectomy and curative radiother- apy in localized prostate cancer: long- term follow-up. Journal of radiation re- search. 2017;58(4):552-558. 2. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-spe- cific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by rad- ical therapy. Results from the Prostate Cancer Results Study Group. BJU inter- national. 2012;109 Suppl 1:22-29. 3. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Local- ized Prostate Cancer. N Engl J Med. 2016;375(15):1415-1424. 4. Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in pros- tate cancer: observational study of mor- tality outcomes. Bmj. 2014;348:g1502. 5. Taguchi S, Fukuhara H, Shiraishi K, et al. Radical Prostatectomy versus Exter- nal Beam Radiotherapy for cT1-4N0M0 Prostate Cancer: Comparison of Patient Outcomes Including Mortality. PloS one. 2015;10(10):e0141123. 6. Vernooij RWM, Cremers R, Jansen H, et al. Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study. Urol Oncol. 2020. 7. Donovan JL, Hamdy FC, Lane JA, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiothera- py for Prostate Cancer. N Engl J Med. 2016;375(15):1425-1437. 8. Lardas M, Liew M, van den Bergh RC, et al. Quality of Life Outcomes after Pri- mary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017;72(6):869-885. 9. Lam TBL, MacLennan S, Willemse PM, et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Con- sensus Statements for Deferred Treat- ment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol. 2019;76(6):790-813. 10. McClure TD, Margolis DJ, Hu JC. Partial gland ablation in the management of prostate cancer: a review. Current opin- ion in urology. 2017;27(2):156-160. 11. Valerio M, Cerantola Y, Eggener SE, et al. New and Established Technology in Focal Ablation of the Prostate: A System- atic Review. Eur Urol. 2017;71(1):17-34. 12. Stabile A, Orczyk C, Hosking-Jervis F, et al. Medium-term oncological out- comes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU international. 2019;124(3):431-440. 13. Guillaumier S, Peters M, Arya M, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clin- ically Significant Nonmetastatic Prostate Cancer. Eur Urol. 2018;74(4):422-429. 14. Shah TT, Peters M, Eldred-Evans D, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Non- metastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol. 2019;76(1):98-105. 15. Barqawi A, Pessoa RR, Al-Musawi M, MacDermott T, O’Donnell CI. The Impact of Performing a 3D Mapping Biopsy Prior to Primary Cryotherapy for the Treatment of Prostate Cancer. Urology. 2020;144:171-176. 16. Tourinho-Barbosa RR, Sanchez-Salas R, Claros OR, et al. Focal Therapy for Local- ized Prostate Cancer with Either High In- tensity Focused Ultrasound or Cryoabla- tion: A Single Institution Experience. The Journal of urology. 2020;203(2):320-330.